Trial Profile
A Prospective Non-interventional Study in Patients With Chronic Obstructive Pulmonary Disease That Evolve to Fixed Long-acting Muscarinic Antagonist/Long-acting beta2-agonist/Inhaled Corticosteroid Triple Therapy, Trimbow
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2021
Price :
$35
*
At a glance
- Drugs Beclometasone/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms TRIVOLVE
- Sponsors Chiesi
- 25 Nov 2021 Status changed from active, no longer recruiting to completed.
- 19 May 2021 Results assessing the inhalation technique and adherence change in patients who evolve from ICS/LABA, LABA/LAMA or loose inhaled triple therapy to extrafine single inhaler triple therapy, presented at the 117th International Conference of the American Thoracic Society.
- 15 Jan 2020 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.